Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of D-Glutamate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.48 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.48 |
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.48 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.48 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.48 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.48 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.48 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.48 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.48 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.48 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.48 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.48 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.48 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 0.48 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 0.48 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | GRM8 | O00222 | 1/20 | 0.60 |
| ▸ | GRM6 | O15303 | 1/20 | 0.60 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Glutamate SCHEMBL30787945 | 0.98 | CYP1A2 (0.58) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| D-Glutamate SCHEMBL1532402 | 0.98 | CYP1A2 (0.62) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| D-Glutamate SCHEMBL541430 | 0.98 | CYP1A2 (0.62) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| D-Glutamate SCHEMBL1782280 | 0.98 | CYP1A2 (0.62) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| D-Glutamate SCHEMBL16336 | 0.98 | CYP1A2 (0.62) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| D-Glutamate SCHEMBL27981176 | 0.98 | CYP1A2 (0.62) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| D-Glutamate SCHEMBL1899059 | 0.98 | CYP1A2 (0.62) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| D-Glutamate SCHEMBL249807 | 0.98 | CYP1A2 (0.62) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| D-Glutamate SCHEMBL82751 | 0.98 | CYP1A2 (0.62) | CYP1A2GRM8GRM6GRIN2DGRIN3B | |
| D-Glutamate SCHEMBL10930916 | 0.95 | CYP1A2 (0.60) | CYP1A2GRM8GRM6GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114762742-A | Extracorporeal blood medication system | 张勇 | 2022-07-19 | — | — | CN | disclosed |
| EP-0843818-B2 | LAWSONIA INTRACELLULARIS CULTIVATION, ANTI-LAWSONIA INTRACELLULARIS VACCINES AND DIAGNOSTIC AGENTS | BOEHRINGER INGELHEIM VETMEDICA INC (US) | 2018-12-19 | — | — | EP | disclosed |
| EP-1403643-B2 | Lawsonia intracellularis cultivation, anti-lawsonia intracelluaris vaccines and diagnostic agents | BOEHRINGER INGELHEIM VETMEDICA INC (US) | 2018-10-03 | — | — | EP | disclosed |
| EP-2199795-B1 | Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents | BOEHRINGER INGELHEIM VETMED (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-1645567-B2 | Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents | BOEHRINGER INGELHEIM VETMED (US) | 2016-01-06 | — | — | EP | disclosed |
| CN-104800841-A | Inactivated vaccine for abortion chlamydia of yaks and preparation method of inactivated vaccine | LANZHOU VETERINARY RES INST CAAS | 2015-07-29 | — | — | CN | disclosed |
| EP-1655607-B1 | Lawsonia intracellularis cultivation, anti-lawsonia intracellularis vaccines and diagnostic agents | BOEHRINGER INGELHEIM VETMED (US) | 2015-05-13 | — | — | EP | disclosed |
| CN-1519311-B | Lawsonia intracellularis cultivation, anti-lawsonia intracelluaris vaccines and diagnostic agents | NOBL LAB INC | 2013-03-13 | — | — | CN | disclosed |
| EP-2199795-A2 | Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents | BOEHRINGER INGELHEIM VETMEDICA, Inc. (US) | 2010-06-23 | — | — | EP | disclosed |
| EP-1403643-B1 | Lawsonia intracellularis cultivation, anti-lawsonia intracelluaris vaccines and diagnostic agents | BOEHRINGER INGELHEIM VETMED (US) | 2009-09-02 | — | — | EP | disclosed |
| CN-1670188-A | Lawsonia intracellularis cultivation, anti-lawsonia intracellularis vaccines and diagnostic agents | NOBL LAB INC (US) | 2005-09-21 | — | — | CN | disclosed |
| EP-0843818-B1 | LAWSONIA INTRACELLULARIS CULTIVATION, ANTI-LAWSONIA INTRACELLULARIS VACCINES AND DIAGNOSTIC AGENTS | BOEHRINGER INGELHEIM VETMED (US) | 2005-02-09 | — | — | EP | disclosed |
| CN-1519311-A | Lawsonia intracellularis cultivation, anti-lawsonia intracelluaris vaccines and diagnostic agents | 诺博实验室股份有限公司 | 2004-08-11 | — | — | CN | disclosed |
| EP-1403643-A1 | Lawsonia intracellularis cultivation, anti-lawsonia intracelluaris vaccines and diagnostic agents | Boehringer Ingelheim Vetmedica, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-0843818-A4 | LAWSONIA INTRACELLULARIS CULTIVATION, ANTI-LAWSONIA INTRACELLULARIS VACCINES AND DIAGNOSTIC AGENTS | BOEHRINGER INGELHEIM NOBL LAB (US) | 2002-02-06 | — | — | EP | disclosed |
| US-5885823-A | BACTERIA STRAIN ATCC NO.55783 ARE INCUBATED IN AN OXYGEN CONCENTRATION OF FROM ABOUT 0 PERCENT TO ABOUT 18 PERCENT, AGITATING THE BACTERIA IN SUSPENSION; VETERINARY MEDICINE | NOBL LABORATORIES, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0843818-A1 | LAWSONIA INTRACELLULARIS CULTIVATION, ANTI-LAWSONIA INTRACELLULARIS VACCINES AND DIAGNOSTIC AGENTS | Boehringer Ingelheim/Nobl Laboratories, Inc. (US) | 1998-05-27 | — | — | EP | disclosed |
| US-5714375-A | INCUBATING INFECTED CELLS IN A REDUCED OXYGEN CONCENTRATION AND MAINTAINING INFECTED CELL IN SUSPENSION BY AGITATION FOR PREFERENTIAL TIME TO INCREASE THE PRODUCTION, AND CULTURING AT LEAST A PORTION OF THE BACTERIA | NOBL LABORATORIES, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| CN-1167146-A | Lawsonia intracellularis culture, vaccine and diagnostic reagent against the same | NOBL LAB INC (US) | 1997-12-10 | — | — | CN | disclosed |
| WO-1996039629-A1 | LAWSONIA INTRACELLULARIS CULTIVATION, ANTI-LAWSONIA INTRACELLULARIS VACCINES AND DIAGNOSTIC AGENTS | BOEHRINGER INGELHEIM/NOBL LABORATORIES, INC. (US) | 1996-12-12 | — | — | WO | disclosed |